Cellectis S.A. American Depositary Shares (CLLS)
Company News
Cellectis présente une stratégie innovante d'ingénierie des cellules T qui exploite les propriétés pro-inflammatoires de l'interleukine 2 (IL-2) dans l'objectif d'améliorer l'efficacité des cellules CAR T contre les tumeurs solides.
Cellectis (CLLS) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
U.S. stocks traded higher toward the end of trading, after the Federal Reserve announced its policy decision. The Dow traded up 0.40% to 33,185.41 while the NASDAQ rose 0.92% to 12,969.54. The S&P 500 also rose, gaining, 0.67% to 4,221.94. Check This Out: $2.8M Bet On This Healthcare Stock? Check Out These 4 Stocks Insiders Are Buying  Leadin...
Penny stocks to watch this week. The post 5 Most Active Penny Stocks Today & Why They’re Moving Now appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.